Voyager Therapeutics (NASDAQ:VYGR) Stock Rating Reaffirmed by Cowen

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “buy” rating reaffirmed by investment analysts at Cowen in a research report issued to clients and investors on Wednesday, AnalystRatings.com reports.

Several other research firms also recently weighed in on VYGR. BidaskClub downgraded Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 27th. Nomura reissued a “buy” rating and set a $37.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and set a $26.00 price target on shares of Voyager Therapeutics in a research report on Monday, August 12th. Zacks Investment Research upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a report on Saturday, October 12th. Finally, ValuEngine cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $27.63.

Voyager Therapeutics stock traded up $0.38 during mid-day trading on Wednesday, hitting $14.86. 263,700 shares of the company were exchanged, compared to its average volume of 451,389. The business’s 50 day simple moving average is $15.86 and its two-hundred day simple moving average is $20.84. The company has a market capitalization of $548.84 million, a P/E ratio of -5.40 and a beta of 2.58. Voyager Therapeutics has a 12-month low of $7.76 and a 12-month high of $28.79.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.42. The company had revenue of $20.43 million during the quarter, compared to the consensus estimate of $3.94 million. Voyager Therapeutics had a negative return on equity of 71.08% and a negative net margin of 106.23%. Analysts forecast that Voyager Therapeutics will post -1.95 EPS for the current year.

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. boosted its holdings in shares of Voyager Therapeutics by 9.8% during the second quarter. BlackRock Inc. now owns 2,079,554 shares of the company’s stock worth $56,605,000 after purchasing an additional 185,582 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Voyager Therapeutics by 12.9% in the second quarter. Vanguard Group Inc. now owns 1,571,862 shares of the company’s stock valued at $42,787,000 after acquiring an additional 180,087 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Voyager Therapeutics by 48.2% in the second quarter. Renaissance Technologies LLC now owns 729,801 shares of the company’s stock valued at $19,865,000 after acquiring an additional 237,500 shares during the last quarter. Invesco Ltd. boosted its holdings in Voyager Therapeutics by 643.6% in the second quarter. Invesco Ltd. now owns 421,155 shares of the company’s stock valued at $11,464,000 after acquiring an additional 364,516 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Voyager Therapeutics by 28.0% in the second quarter. JPMorgan Chase & Co. now owns 326,643 shares of the company’s stock valued at $8,590,000 after acquiring an additional 71,451 shares during the last quarter. Institutional investors and hedge funds own 78.63% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

Recommended Story: How does a margin account work?

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.